[1] GAO R, LIU Y, GJESING A P, et al. Evaluation of a target
region capture sequencing platform using monogenic diabetes as a study-model[J]. BMC Genet, 2014,15(1):1-9.
[2]THANABALASINGHAM G, OWEN K R. Diagnosis and
management of maturity onset diabetes of the young (MODY)[J]. BMJ, 2011(343):d6044.
[3]COLCLOUGH K, BELLANNE-CHANTELOT C, SAINT-
MARTIN C, et al. Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha and 4 alpha in maturity-onset diabetes of the young and hyperinsulinemic hypoglycemia[J]. Hum Mutat, 2013,34(5):669-685.
[4]ARYA V B, RAHMAN S, SENNIAPPAN S, et al. HNF4A
mutation: switch from hyperinsulinaemic hypoglycaemia to maturity-onset diabetes of the young, and incretin response[J]. Diabet Med, 2014,31(3):e11-15.
[5]PRUHOVA S, EK J, LEBL J, et al. Genetic epidemiology of
MODY in the Czech republic: new mutations in the MODY genes HNF-4alpha, GCK and HNF-1alpha[J]. Diabetologia, 2003,46(2):291-295.
[6]PEARSON E R, BOJ S F, STEELE A M, et al. Macrosomia and
hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations in the HNF4A gene[J]. PLoS Med, 2007,4(4):e118.
[7]FAJANS S S, BROWN M B. Administration of sulfonylureas can
increase glucose-induced insulin secretion for decades in patients with maturity-onset diabetes of the young[J]. Diabetes Care, 1993,16(9):1254-1261.
[8]MARTIN D, BELLANNE-CHANTELOT C, DESCHAMPS I, et
al. Long-term follow-up of oral glucose tolerance test-derived glucose tolerance and insulin secretion and insulin sensitivity indexes in subjects with glucokinase mutations (MODY2)[J]. Diabetes Care, 2008,31(7):1321-1323.
[9]STEELE A M, SHIELDS B M, SHEPHERD M, et al. Microvascular complication risk in patients with 50 years of moderate hyperglycaemia: are target ranges for glycaemic control appropriate[J]. Diabet Med, 2011, 28(Suppl 1): 28.
[10]RUBIO-CABEZAS O,HATTERSLEY A T,NJOLSTAD P R,et al.The diagnosis and management of monogenic diabetes in children and adolescents[J]. Pediatric diabetes, 2014, 15(s20): 47-64.
[11]SHIELDS B M, HICKS S, SHEPHERD M H, et al. Maturity-onset diabetes of the young (MODY): how many cases are we missing?[J]. Diabetologia, 2010, 53(12): 2504-2508.
[12]HARRIES L W, ELLARD S, STRIDE A, et al. Isomers of the TCF1 gene encoding hepatocyte nuclear factor-1 alpha show differential expression in the pancreas and define the relationship between mutation position and clinical phenotype in monogenic diabetes[J]. Hum Mol Genet, 2006,15(14):2216-2224.
[13]BOWMAN P, FLANAGAN S E, EDGHILL E L, et al.
Heterozygous ABCC8 mutations are a cause of MODY[J]. Diabetologia, 2012,55(1):123-127.
[14]FAJANS S S, BELL G I, PAZ V P, et al. Obesity and
hyperinsulinemia in a family with pancreatic agenesis and MODY caused by the IPF1 mutation Pro63fsX60[J]. Transl Res, 2010,156(1):7-14.
[15]KARIM M A, WANG X, HALE T C, et al. Insulin Promoter Factor 1 variation is associated with type 2 diabetes in African Americans[J]. BMC medical genetics, 2005, 6(1): 1.
[16]SHEN H, FRIDLEY B L, SONG H, et al. Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer[J]. Nat Commun, 2013,4(3):67-68.
[17]Kim H S, Noh J H, Hong S H, et al. Rosiglitazone stimulates the
release and synthesis of insulin by enhancing GLUT-2, glucokinase and BETA2/NeuroD expression[J]. Biochem Biophys Res Commun, 2008,367(3):623-629.
[18]RUBIO-CABEZAS O, MINTON J A, KANTOR I, et al.
Homozygous mutations in NEUROD1 are responsible for a novel syndrome of permanent neonatal diabetes and neurological abnormalities[J]. Diabetes, 2010,59(9):2326-2331.
[19]MALECKI M T, JHALA U S, ANTONELLIS A, et al. Mutations in NEUROD1 are associated with the development of type 2 diabetes mellitus[J]. Nat Genet, 1999,23(3):323-328.
[20]NEVE B, FERNANDEZ-ZAPICO M E, ASHKENAZI-
KATALAN V, et al. Role of transcription factor KLF11 and its diabetes-associated gene variants in pancreatic beta cell function[J]. Proc Natl Acad Sci USA, 2005,102(13):4807-4812.
[21]TRUTY M J, LOMBERK G, FERNANDEZ-ZAPICO M E, et al. Silencing of the transforming growth factor-beta (TGFbeta) receptor II by Kruppel-like factor 14 underscores the importance of a negative feedback mechanism in TGFbeta signaling[J]. J Biol Chem, 2009,284(10):6291-6300.
[22]MA L, HANSON R L, QUE L N, et al. Association analysis of Kruppel-like factor 11 variants with type 2 diabetes in Pima Indians[J]. J Clin Endocrinol Metab, 2008,93(9):3644-3649.
[23]RAEDER H, JOHANSSON S, HOLM P I, et al. Mutations in the CEL VNTR cause a syndrome of diabetes and pancreatic exocrine dysfunction[J]. Nat Genet, 2006,38(1):54-62.[24]VESTERHUS M, RAEDER H, AURLIEN H, et al. Neurological features and enzyme therapy in patients with endocrine and exocrine pancreas dysfunction due to CEL mutations[J]. Diabetes Care, 2008,31(9):1738-1740.
[25]JO W, ENDO M, ISHIZU K, et al. A novel PAX4 mutation in a Japanese patient with maturity-onset diabetes of the young[J]. Tohoku J Exp Med, 2011,223(2):113-118.
[26]LEMPAINEN J, HERMANN R, VEIJOLA R, et al. Effect of the PTPN22 and INS risk genotypes on the progression to clinical type 1 diabetes after the initiation of β-cell autoimmunity[J]. Diabetes, 2012,61(4):963-966.
[27]HANEDA M, POLONSKY K S, BERGENSTAL R M, et al.
Familial hyperinsulinemia due to a structurally abnormal insulin. Definition of an emerging new clinical syndrome[J]. N Engl J Med, 1984,310(20):1288-1294.
[28]STOY J, EDGHILL E L, FLANAGAN S E, et al. Insulin gene mutations as a cause of permanent neonatal diabetes[J]. Proc Natl Acad Sci USA, 2007,104(38):15040-15044.
[29]BONNEFOND A, LOMBERK G, BUTTAR N, et al. Disruption
of a novel Kruppel-like transcription factor p300-regulated pathway for insulin biosynthesis revealed by studies of the c.-331 INS mutation found in neonatal diabetes mellitus[J]. J Biol Chem, 2011,286(32):28414-28424.
[30]BOROWIEC M, LIEW C W, THOMPSON R, et al. Mutations at
the BLK locus linked to maturity onset diabetes of the young and beta-cell dysfunction[J]. Proc Natl Acad Sci USA, 2009,106(34):14460-14465.
[31]INCE D A, SAHIN N M, ECEVIT A, et al. Congenital
hyperinsulinism in a newborn with a novel homozygous mutation (p. Q392H) in the ABCC8 gene[J]. Journal of Pediatric Endocrinology and Metabolism, 2014, 27(11-12):1253-1255.
[32]JINDAL R, AHMAD A, SIDDIQUI M A, et al. Novel mutation c.597_598dup in exon 5 of ABCC8 gene causing congenital hyperinsulinism[J]. Diabetes Metab Syndr, 2014,8(1):45-47.
[33]JOHANSSON S, IRGENS H, CHUDASAMA K K, et al. Exome sequencing and genetic testing for MODY[J]. PLoS ONE, 2012,7(5):e38050.
[34]ANIK A, CATLI G, ABACI A, et al. A novel activating ABCC8 mutation underlying neonatal diabetes mellitus in an infant presenting with cerebral sinovenous thrombosis[J]. J Pediatr Endocrinol Metab, 2014,27(5-6):533-537.
[35]BONNEFOND A, PHILIPPE J, DURAND E, et al. Whole-exome sequencing and high throughput genotyping identified KCNJ11 as the thirteenth MODY gene[J]. PLoS ONE, 2012,7(6):e37423.
[36]QIN L J, LV Y, HUANG Q Y. Meta-analysis of association of common variants in the KCNJ11-ABCC8 region with type 2 diabetes[J]. Genet Mol Res, 2013,12(3):2990-3002.
[37]SU C, GONG C, SANGER P, et al. Long-term follow-up and mutation analysis of 27 chinese cases of congenital hyperinsulinism[J]. Horm Res Paediatr, 2014,81(3):169-176.
[38]KLEN J, DOLZAN V, JANEZ A. CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients[J]. Eur J Clin Pharmacol, 2014,70(4):421-428.
|
